Navigation Links
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies

or in combination were administered at different time points. Treatment with the combination regimen reduced the growth of small tumors by 80% to 82% and of well-established tumors by 92% to 94%. The anti-tumor effect of the combination regimen was significantly superior to that of the individual treatments (P < 0.01). Yet the combination therapy was no more toxic to the mice than was docetaxel alone as judged by physical signs and body weight changes.

Tumor microvessel density, which is correlated with tumor growth rates, was further reduced in tumors treated with the combination regimen compared with tumors from single agent-treated animals. In addition, serum PSA levels in combination-treated mice registered a significantly greater decrease (P < 0.05) in one of the tumor models compared to the decrease seen in either the docetaxel-treated or 2aG4-treated animals.

Bavituximab is a targeted monoclonal antibody that binds to a phospholipid called phosphatidylserine, which is located on the inside of normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, thus creating a specific target for anti-cancer treatments. Once bound to the tumor blood vessels, bavituximab alerts the body's immune system to attack the tumor's blood supply, stopping the flow of oxygen and nutrients to the tumor cells and resulting in tumor cell death. As an anti-cancer immunotherapeutic, bavituximab may have broad potential in a wide variety of solid cancers. It is currently in Phase Ia cancer safety trials as a monotherapy and in a Phase Ib trial in combination with docetaxel and other chemotherapy agents in patients with advanced solid cancers, including prostate, breast and lung cancer. Interim data indicate that more than half of the cancer patients in this study who have completed treatment to date were assessed as demonstrating stable disease or an objective response.

Prostate cancer is the most commonly diagnosed c
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:3/31/2015)... DUBLIN , Mar. 30, 2015 Research ... announced the addition of the "Eurpoean Automatic ... Fully-Automated), End-User (Pre-Hospitals, Public Access Market, Hospitals, Alternate ... report to their offering. The European ... grow at a CAGR of 10.9% from 2014 ...
(Date:3/31/2015)... , March 31, 2015  The efficacy of ... highlighted in a recently published study 1 of ... prevention research team, including Curtis Donskey , M.D.  ... run for the same length of time from the ... (PU-UV) unit.  The results showed surprisingly low pathogen kill ...
(Date:3/31/2015)... DALLAS , March 31, 2015 ... H1 2015" therapeutic market research report of 68 ... its online business intelligence library. The ... information on the therapeutic development for Pemphigus ... therapeutics assessment by drug target, mechanism of action ...
Breaking Medicine Technology:Eurpoean Automatic External Defibrillators (Semi-Automated, Fully-Automated) Market 2015-2019 - Pre-Hospitals, Public Access Market, Hospitals, Alternate Care Market, Home Analysis 2Eurpoean Automatic External Defibrillators (Semi-Automated, Fully-Automated) Market 2015-2019 - Pre-Hospitals, Public Access Market, Hospitals, Alternate Care Market, Home Analysis 3VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 2VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 3VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 4Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4
... antibody successfully targets human leukemic stem cells, ... company, has today presented data at the American ... the promising,pre-clinical activity of a novel monoclonal antibody, ... AML is an aggressive cancer of white ...
... Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast ... ... (Nasdaq: MGRM ) today announced five posters to be,presented at the 30th ... - 16, 2007. Following are details for,each embargoed session:, -- Friday, ...
Cached Medicine Technology:Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3
(Date:3/31/2015)... March 31, 2015 Calling all runners, walkers ... and other tick-borne diseases! The first annual “Lyme Walk & ... Park in Stamford, CT. The event, hosted by Lyme ... will raise funds to support research and education about Lyme ... to all ages and abilities, will feature 5K and 10K ...
(Date:3/31/2015)... March 31, 2015 Many people, including ... basketball, rock climbing, and cycling are only for able-bodied ... at Memorial Rehabilitation Institute aims to change that thinking. ... System, will host an Adaptive Sports Expo on Saturday, ... Regional Hospital South in Hollywood. , The event ...
(Date:3/31/2015)... 31, 2015 Indosoft, developer of the Q-Suite ... support in development of their 5.x line. The industry ... been deployed around the world for more than a decade. ... a telephony platform, Q-Suite can fully embrace newer Asterisk features ... center software on Asterisk for more than a decade. The ...
(Date:3/31/2015)... KL Malaysia (PRWEB) March 31, 2015 ... need and requirement for education in a drastically different ... way in which learning and training content is being ... is being impacted by technology in an unprecedented way ... everyone, said Wemel Cumavoo, co-founder and CEO, My Mobile ...
(Date:3/31/2015)... The Walk a Mile Project, as part of their documentary ... their 3rd research sequence. The new sequence focuses on ... was and is a massive component of GMO regulation in ... World Films. “We started our research by going way ... food supply, just to get a bird's eye and big ...
Breaking Medicine News(10 mins):Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2
... Researchers at North Carolina State University have successfully modified ... specific cells inside the human body, without affecting surrounding ... of times smaller than the width of a human ... with greatly reduced, or even eliminated, side effects. , ...
... 12 Harris Corporation,(NYSE: HRS ... has been awarded a ten-year contract by ... to provide network,management and IT services for ... First Infrastructure Services (HFIS) contract includes,software and ...
... Feb. 12 When an emergency squad pulls up to ... New York, chances are the paramedics have received a new ... the University of Rochester Medical Center.The institution is ... (EMTs) and paramedics with video podcast lessons downloadable onto iPods ...
... in blindness and crumbling teeth have found a single ... tooth development. , A previously undiscovered and ... has been uncovered by researchers from the University of ... village in the war-torn Gaza strip. , Funded ...
... The Terri Lynne Lokoff Child Care Foundation (TLLCCF) ... TYLENOL(R) National Child Care Teacher Awards(TM). Fifty exemplary ... the United States and on U.S. Military bases in ... to maintaining high-quality child care practices and dedication to ...
... the body quickly needs to restore the vital blood volume. ... in the bone marrow. These hematopoietic stem cells remain dormant ... case of injury and loss of blood. Then they immediately ... cells. This has recently been shown by a group of ...
Cached Medicine News:Health News:Nanoparticle 'smart bomb' targets drug delivery to cancer cells 2Health News:Health First Healthcare System Awards Harris Corporation Enterprise-wide Network Management and IT Services Contract 2Health News:Health First Healthcare System Awards Harris Corporation Enterprise-wide Network Management and IT Services Contract 3Health News:University of Rochester Launches iTraining for Emergency Responders 2Health News:Gaza strip families give first clue to condition causing blindness and tooth decay 2Health News:Terri Lynne Lokoff Child Care Foundation Announces Recipients of the 2009 Terri Lynne Lokoff/Children's TYLENOL(R) National Child Care Teacher Awards(TM) 2Health News:Stem cells: Deathly awakening by interferon 2
... Leica ASP300 smart tissue processor features superior ... ASP300 is a fully enclosed, stand-alone system ... samples. This new tissue processor combines proven ... touch screen and easy to use,yet powerful ...
... 120 represents a new tissue infiltration instrument, ... a masterly way. The robust caroussel design ... smallest space. The instrument includes either 10 ... reagent and 3 paraffin containers. Up to ...
... electronic, motorized rotary microtomes ... applications of paraffin, semi-thin ... specimens in clinical, research, ... instruments display extra-ordinary ergonomic ...
... heavy-duty sectioning system is the standard microtome for ... real working animal. ,Large specimens up to 250 ... bone or teeth and whole organs (brain, lung, ... accessories, specially designed for paraffin and resin embedded ...
Medicine Products: